Cellectricon strengthens Scientific Advisory Board with appointment of Professor Marc Bickle
Building on its success, Cellectricon is continuing to enhance its expertise in Drug Discovery with the addition of another highly respected specialist, Professor Marc Bickle, to its Scientific Advisory Board.
Professor Bickle obtained his PhD at the Biozentrum of the University of Basel, Switzerland, before moving to Cambridge, UK and later Lyon, France, where he was involved in the creation of a biotech company. Currently, he heads the screening facility of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, where he is developing chemical genomic cellular assays using automated microscopy, image analysis and multivariate statistics.
He brings extensive technological experience to Cellectricon’s Advisory board, and will specifically support work with live cell high content screening, as well as data and image analysis.
The partnership promises to further advance Cellectricon’s Discovery Services, giving clients ever more superior outcomes.
For more information on Cellectricon’s Pain and CNS Discovery Services, please visit the Discovery Services Page